It’s another one gone and another one gone for Amgen, as the pharmaceutical giant reported the latest clinical stoppage for a bispecific T-cell engager, or BiTE, therapy.

Sage Therapeutics terminated two long-suspended phase 3 zuranolone clinical trials after talks with the FDA led it to believe it can seek approval in major depressive disorder (MDD) without data from those studies. The biotech shared the update alongside news of a delay to data from another phase 3 because of slow enrollment during the pandemic.

Bausch Health outlined plans to spin out its aesthetics devicemaker Solta Medical as it looks to further chip away at a mountain of debt on top of paying out $350 million to holders of outstanding senior notes this week.

With $105 million deposited in the bank less than four months ago, Arch Oncology is putting its series C resources to use.

Coya Therapeutics is planning a phase 2b trial to support an FDA approval for an ALS candidate as the biotech positions for another round of funding by year’s end and a potential IPO down the road.

Abbott debuted its latest insertable cardiac monitor, equipped with new features to help clinicians sift a constant flow of heart rhythm data for potentially dangerous conditions such as atrial fibrillation.

They say the surest path to a person’s heart is through their stomach, but according to MindMics, it might actually be through the ears.

Immunotherapy treatments such as checkpoint-inhibiting drugs have radically improved the treatment paradigm for a range of cancers, with one notable exception: prostate tumors, which are considered “cold,” or resistant to an immune attack. Now, a team helmed by the University of Michigan Rogel Cancer Center has found a protein target that it believes could make prostate tumors amenable to immunotherapy—and a drug candidate to target it.

The FDA has cleared a system that creates accurate, three-dimensional holograms of a patient’s organs, giving surgeons a new opportunity to interact with their anatomy and orient themselves prior to any procedure.

The accelerated approval of Biogen’s Aduhelm has caught the eye of AbbVie, which plans to push an Alzheimer’s disease candidate that potentially has a better safety profile into the clinic by year’s end or early next year.